BioTuesdays

Tag - Andrew Berens

Aura Biosciences

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

Theseus Pharmaceuticals

SVB Leerink starts Theseus Pharma at OP; PT $28

SVB Leerink launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with an “outperform” rating and $28 price target. The stock closed at $17.12 on Oct. 29. Theseus is a biopharmaceutical company focused on “pan...

Elevation-Oncology

SVB Leerink starts Elevation Oncology at OP; PT $20

SVB Leerink launched coverage of Elevation Oncology (NASDAQ:ELEV) with an “outperform” rating and $20 price target. The stock closed at $12.10 on July 19. Elevation is a clinical development-stage biotech company...

Merus Logo

SVB Leerink starts Merus at OP; PT $33

SVB Leerink launched coverage of Merus NV (NASDAQ:MRUS) with an “outperform” rating and $33 price target. The stock closed at $22.04 on March 15. Merus is focused on developing novel bispecific and trispecific...

Cullinan-Oncology-Logo

SVB Leerink starts Cullinan at OP; PT $52

SVB Leerink initiated coverage of Cullinan Management (NASDAQ:CGEM) with an “outperform” rating and $52 price target. The stock closed at $33.77 on Feb. 1. Cullinan is leveraging a unique “Hub-and-Spoke”...

zentalis logo

SVB Leerink starts Zentalis Pharma at OP; PT $45

SVB Leerink initiated coverage of Zentalis Pharmaceuticals (NASDAQ:ZNTL) with an “outperform” rating and $45 price target. The stock closed at $31.76 on April 27. Zentalis’ lead compound is an oral selective estrogen...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.